The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...
GlobalData on MSN
Pfizer reports topline data from SigVie-002 study for NSCLC
The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.
The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...
Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...
Things are going from bad to worse for the pharmaceutical giant.
Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results